VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

VJVirtual | Ruxolitinib and decitabine in patients with post-MPN AML

Prithviraj Bose, MD, of The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale, study design and results from a Phase I/II study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter